| Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease S Møller, JH Henriksen Heart 87 (1), 9-15, 2002 | 921* | 2002 |
| Cardiovascular complications of cirrhosis S Møller, JH Henriksen Postgraduate medical journal 85 (999), 44-54, 2009 | 640 | 2009 |
| Bacterial translocation and cardiovascular complications of cirrhosis. Authors' response to letter S Møller, JH Henriksen Gut 57, 1181-1182, 2008 | 640* | 2008 |
| Interactions of the heart and the liver S Møller, M Bernardi European heart journal 34 (36), 2804-2811, 2013 | 514 | 2013 |
| Cirrhotic cardiomyopathy S Møller, JH Henriksen Journal of hepatology 53 (1), 179-190, 2010 | 489 | 2010 |
| Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites A Krag, F Bendtsen, JH Henriksen, S Møller Gut 59 (01), 105-110, 2010 | 477 | 2010 |
| Serum YKL-40 is increased in patients with hepatic fibrosis JS Johansen, P Christoffersen, S Møller, PA Price, JH Henriksen, ... Journal of hepatology 32 (6), 911-920, 2000 | 339 | 2000 |
| Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity … JH Henriksen, JP Gøtze, S Fuglsang, E Christensen, F Bendtsen, S Møller Gut 52 (10), 1511-1517, 2003 | 332 | 2003 |
| Cirrhotic cardiomyopathy: pathogenesis and clinical relevance S Wiese, JD Hove, F Bendtsen, S Møller Nature reviews Gastroenterology & hepatology 11 (3), 177, 2014 | 315 | 2014 |
| Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy N Kimer, A Krag, S Møller, F Bendtsen, LL Gluud Alimentary pharmacology & therapeutics 40 (2), 123-132, 2014 | 240 | 2014 |
| The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis S Møller, F Bendtsen Liver International 38 (4), 570-580, 2018 | 218 | 2018 |
| The sympathetic nervous system in liver disease JH Henriksen, S Møller, H Ring-Larsen, NJ Christensen Journal of hepatology 29 (2), 328-341, 1998 | 203 | 1998 |
| Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients S Møller, EF Hansen, U Becker, K Brinch, JH Henriksen, F Bendtsen Liver 20 (1), 51-59, 2000 | 187 | 2000 |
| Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome A Krag, S Møller, JH Henriksen, NH Holstein‐Rathlou, FS Larsen, ... Hepatology 46 (6), 1863-1871, 2007 | 178 | 2007 |
| Dyssynchronous electrical and mechanical systole in patients with cirrhosis JH Henriksen, S Fuglsang, F Bendtsen, E Christensen, S Møller Journal of hepatology 36 (4), 513-520, 2002 | 178 | 2002 |
| Acute non-selective β-adrenergic blockade reduces prolonged frequency-adjusted Q–T interval (QTc) in patients with cirrhosis JH Henriksen, F Bendtsen, EF Hansen, S Møller Journal of hepatology 40 (2), 239-246, 2004 | 177 | 2004 |
| Soluble CD 163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis H Grønbaek, TD Sandahl, C Mortensen, H Vilstrup, HJ Møller, S Møller Alimentary pharmacology & therapeutics 36 (2), 173-180, 2012 | 176 | 2012 |
| Lactate metabolism in chronic liver disease JB Jeppesen, C Mortensen, F Bendtsen, S Møller Scandinavian journal of clinical and laboratory investigation 73 (4), 293-299, 2013 | 167 | 2013 |
| Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis S Møller, F Bendtsen, JH Henriksen Gastroenterology 109 (6), 1917-1925, 1995 | 156 | 1995 |
| Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? JS Johansen, S Møller, PA Price, F Bendtsen, J Junge, C Garbarsch, ... Scandinavian journal of gastroenterology 32 (6), 582-590, 1997 | 153 | 1997 |
